News

Complication rates decline among diabetes patients


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

The rate of diabetes-related myocardial infarction has fallen almost 68% since 1990, according to an analysis of several federal data sources.

From 1990 to 2010, the rate of acute MI among adults with diabetes fell from 141 cases/10,000 diabetes patients to 45.5/10,000, Edward W. Gregg, Ph.D. and associates reported.

The rate of diabetes-related stroke was down 53% from 1990 to 2010, dropping from 112 cases/10,000 patients to 53/10,000. Lower-extremity amputations declined by 51% over the same period, as the rate went from 58 cases/10,000 to 28/10,000. The rate of end-stage renal disease fell from 28 cases/10,000 in 1990 to 20/10,000 in 2010 for a 28% decline.

These decreases among diabetes patients surpassed the reductions seen among the nondiabetic population over the same time period, but "the large increase in the number of prevalent cases of diabetes" suggests that "the total burden, or absolute number of cases of complications, will probably continue to increase in the coming decades," wrote Dr. Gregg of the Centers for Disease Control and Prevention, Atlanta, and his associates (N. Engl. J. Med. 2014;370:1514-23).

The analysis involved data from the National Hospital Discharge Survey, the U.S. Renal Data System, and the National Health Interview Survey.

rfranki@frontlinemedcom.com

Recommended Reading

Adding HbA1c doesn’t improve CVD risk assessment
MDedge Endocrinology
Aleglitazar failed to reduce cardiovascular events in type 2 diabetes
MDedge Endocrinology
Bariatric surgery’s benefit persists in type 2 diabetes
MDedge Endocrinology
Post procedure clopidogrel cuts amputation rates
MDedge Endocrinology
FDA panel backs approval of inhaled insulin for type 1 and 2 diabetes
MDedge Endocrinology
Weekly exenatide shows long-term efficacy in type 2 diabetes
MDedge Endocrinology
Stress cardiac magnetic resonance feasible and prognostic in obese patients
MDedge Endocrinology
Newcomer misses noninferiority mark against established GLP-1 receptor agonist
MDedge Endocrinology
Diabetes prevalence increases, but so does diabetes control
MDedge Endocrinology
FDA approves GLP-1 receptor agonist albiglutide for type 2 diabetes
MDedge Endocrinology